Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
We strompelen in stijl het oude jaar uit. Het management van het LSP Fund voert de volgende oorzaken aan: While the capital markets performed very well in 2021, healthcare and biotech in particular have dramatically underperformed. Much has already been written to try to explain this dichotomy. Why is the market negative for biotech when it is innovation in healthcare which is ‘saving’ us from the pandemic? We can point to the good performance of the sector in 2020 in the wake of the first wave of the pandemic – were valuation too high at the start of 2021? Is it the on-going pandemic and a flight from risk? Biotech companies are certainly considered to be at the high end of any risk assessment. Has there been a lack of M&A transactions? It is true that this year lacked the kind of M&A transactions which get investors excited about the sector. The excitement about healthcare in 2020 led to several US fund seeing very large inflows – this appears to have led to a bubble at the start of 2021 as these fund had to rapidly deploy large amounts of capital (ARK Invest being an example). But even taking this spike and re-set seen in February/March of this year out of the equation, the sector has underperformed. There are several sector specific factors which came into play. With a new administration in the White House, the question of drug pricing was back in focus. This always causes uncertainly until the new strategy is defined. A second major impact of the new administration is the lack of leadership at FDA. The agency is under pressure due to increased work relating to the pandemic, there have been an unprecedented number of clinical trials relating to vaccine and anti-viral drug development which needed attention. Not to mention the Emergency Use Authorisations which were necessary. This has resulted, or so it seems, in a larger then usually number of delays to drug authorisations and above average number of trials being put on clinical hold. Any factors suggesting increased risk to drug development are negative for biotech investor sentiment. So, what does all this mean? In essence – it is not clear why biotech has underperformed so dramatically in 2021. Most likely it is a combination of all the factors mentioned about – the perfect storm so to speak. There have been many positive, impactful events in our portfolio companies this year, which have not resulted in positive share price performance. However, we believe that the underlying value of these companies has increased and will be reflected eventually. There are several catalysts to come in the portfolio this year. If these are positive, they will increase the underlying value and we are hopeful that this will also be reflected in the share price. If that does not happen, then the large number of pharma and larger biotech companies which strong balance sheets will no doubt take notice.
Zoals hierboven was het wel een dramajaar Het is dat ik Kadmon en Trillium in mijn porto had . Moge 2022 beter zijn voor de Biotech sector Nog verder de beste wensen voor 2022.
Ontop1 schreef op 2 januari 2022 14:09 :
Zoals hierboven was het wel een dramajaar
Het is dat ik Kadmon en Trillium in mijn porto had .
Moge 2022 beter zijn voor de Biotech sector
Nog verder de beste wensen voor 2022.
Ook de beste wensen! Voor veel particuliere investeerders in Affimed is 2021 inderdaad op een rampjaar uitgelopen omdat, traditiegetrouw, de meesten zullen zijn ingestapt toen het aandeel naar $12 schoot. Die zie je dus niet zo snel terug. Ik vermoed verder dat instituten (als een Pictet) hier dankbaar gebruik van hebben gemaakt. De enige domper voor de onderneming was in mijn ogen dan ook het terugtrekken van Genentech uit het BCMA programma dat jammer genoeg de spectaculaire resultaten van AFM13+ cbNK cellen overschaduwde. Was dat terecht? Ik denk van niet: in de race naar een medicijn tegen de ziekte van Kahler is inmiddels een ware lawine van kandidaten (ook bij Roche zelf) ontstaan die inderdaad veelbelovend zijn. Maar CD30 en EFGR? Daar heeft Affimed in mijn beleving toch een verdraaid goede concurrentiepositie. Het zelfde kan voor CD123 gezegd worden. Ik ben dus hoopvol gestemd voor het nieuwe jaar.
In 2021 was de koers maar 1x bij de weekafsluiting lager dan nu :-(
RW1963 schreef op 4 januari 2022 18:00 :
In 2021 was de koers maar 1x bij de weekafsluiting lager dan nu :-(
Het volume is lager dan.normaal dus het zegt niet veel. Het is nu even een nieuwsloze periode en het biosentiment is ook even negatief.
HEIDELBERG, Germany, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that its Chief Executive Officer Dr. Adi Hoess will present at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 10:30 a.m. Eastern Standard Time / 16:30 Central European Time. A live webcast of the presentation may be accessed on Affimed’s website at www.affimed.com/investors/webcasts-an... or at jpmorgan.metameetings.net/events/heal... and will be available for 30 days following the event. For more information or to schedule a one-on-one meeting with Affimed management, please contact Alex Fudukidis via email at a.fudukidis@affimed.com or phone at +1 (917) 436-8102.
Vandaag maar effe niet kijken Het is wat het is helaas
Bizar hoor. XBI is in een totale vrije val beland en sleurt alles mee naar beneden. Herstel gaat wel even duren ben ik bang. Uitzitten maar, het is niet anders
harvester schreef op 5 januari 2022 08:43 :
[...]
Het volume is lager dan.normaal dus het zegt niet veel.
Het is nu even een nieuwsloze periode en het biosentiment is ook even negatief.
Opvallend was dat in de laatste minuten het volume fors omhoog ging zonder dat de koers (nog) verder door het putje ging. Als biotechbelegger is het de kunst je te blijven focussen op de gang van zaken in de kliniek. De rest zal wel een keer overwaaien. Wel prettig natuurlijk dat je niets moet verkopen. In de VS zou dat zo maar anders kunnen zijn. Er zijn waarschijnlijk zat hedge funds die niet vies zijn van leverage.
Affimed Announces Completion of Enrollment in REDIRECT, the Registration-Directed Study of AFM13 in PTCL, and Provides Business Update Enrollment of REDIRECT study (AFM13-202) is completed; topline clinical readout expected in 2H 2022 FDA approves protocol amendment to allow for (i) enrollment of up to 40 patients at the highest dose level, and (ii) treatment of patients with more than two cycles in the investigator sponsored trial of cord blood-derived natural killer (cbNK) cells pre-complexed with AFM13 (AFM13-104) Broad development strategy launched for AFM24 – enrollment initiated in three studies addressing major EGFR-expressing solid tumor indications including non-small cell lung and colorectal cancer For AFM28 a first in human study initiation is planned for second half of 2022 Cash position provides funding into 2H 2023 HEIDELBERG, Germany, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has completed enrollment in the REDIRECT study and provided a business update. REDIRECT, also known as AFM13-202 (NCT04101331), is a registration-directed phase 2 open-label, multicenter, global study investigating the efficacy and safety of AFM13 monotherapy in patients with relapsed or refractory CD30-positive peripheral T-cell lymphoma (PTCL). Affimed expects to report topline data from the REDIRECT study in the second half of 2022. “Completing the enrollment in the registration directed trial of AFM13, our lead innate cell engager, is an important milestone for us and reflects our ability to progress and advance our clinical pipeline. The high response rates reported in December 2021 from our combination study with natural killer cells in Hodgkin Lymphoma represent a marked expansion of the business opportunity of AFM13. We are looking forward to solidifying the opportunity for AFM13 when we report additional data this year,” said Dr. Adi Hoess, Chief Executive Officer of Affimed. “Data generated from multiple AFM13 trials provide us with confidence in the development strategy for AFM24 and AFM28, for which we expect to provide additional updates during 2022.” The REDIRECT trial protocol, in addition to the registration relevant cohorts A and B in PTCL, includes an arm to investigate AFM13 therapy in patients with Transformed Mycosis Fungoides (TMF), which is exploratory and not relevant to the potential consideration for accelerated approval. As previously announced, recruitment of TMF patients was paused due to the COVID-19 pandemic. At this time, Affimed has decided not to pursue the investigation of AFM13 therapy in patients with TMF due to the continuing impact of the COVID-19 pandemic and the completion of enrollment of the registration-directed portion of the trial.
Update on Other Programs AFM13 (CD30/CD16A ICE®) The United States Food and Drug Administration (FDA) has approved a proposed amendment to the AFM13-104 trial protocol to increase the patient population treated at the recommended phase 2 dose (RP2D) to 40 CD30-positive lymphoma patients, including both Hodgkin Lymphoma (HL) patients and non-Hodgkin Lymphoma (NHL) patients, and allow for the treatment of patients with more than the two cycles of therapy, at the investigator’s discretion. With the approval of the protocol amendment, The University of Texas MD Anderson Cancer Center (MDACC) has initiated enrollment of patients into the phase 2 portion of the trial, triggering an undisclosed milestone payment to MDACC which Affimed expects to make during the first quarter of 2022. AFM13-104 is an investigator sponsored trial (IST) at MDACC investigating the treatment of CD30-positive lymphoma patients with cbNK cells, pre-complexed with AFM13. In December 2021, Affimed reported updated data from the trial, including a 100% objective response rate after a single cycle of treatment for the 13 patients treated at the RP2D of 1x108 cbNK cells precomplexed with AFM13 followed by 3 weekly infusions of AFM13. All three patients treated at the RP2D with at least 6 months of follow-up remained in complete response as of the cutoff date. AFM24 (EGFR/CD16A ICE®) During the fourth quarter of 2021, Affimed announced that it had identified the RP2D for AFM24 monotherapy of 480 mg weekly in patients with EGFR-expressing solid tumors. With the achievement of this milestone, Affimed has now embarked on a broad development strategy for AFM24, which includes the initiation of three studies investigating various EGFR-expressing solid tumor indications. Affimed has initiated enrollment in the expansion phase of the monotherapy AFM24 trial at the RP2D. The trial includes patients with renal cell carcinoma (clear cell), non-small cell lung cancer (EGFR-mutant) and colorectal cancer. Affimed also initiated enrollment in two separate phase 1/2a combination studies. The first is investigating the combination of AFM24 with SNK01 (ex vivo expanded and activated autologous NK cell therapy from NKGen Biotech) to treat patients with non-small cell lung cancer (NSCLC, EGFR-wildtype), squamous cell carcinoma of the head and neck, and colorectal cancer. The second study will investigate the combination of AFM24 with Roche’s atezolizumab, an anti-PD-L1 checkpoint inhibitor to treat patients with non-small cell lung cancer (EGFR-wildtype), gastric and gastroesophageal junction adenocarcinoma and pancreatic/hepatocellular/biliary tract cancer. Affimed expects to report data updates from the AFM24 trials during 2022. AFM28 (CD123/CD16A ICE®) AFM28 is currently being prepared for clinical evaluation with an IND filing planned for the first half of 2022 and a first in human study is planned to start in second half of 2022. Initial preclinical data for AFM28 was presented at the 63rd American Society of Hematology Annual Meeting (ASH) in December 2021, demonstrating antibody-dependent cell-mediated cytotoxicity (ADCC) even at low CD123 expression which was more pronounced compared to conventional anti-CD123 antibodies. In addition, AFM28 showed a 100-fold more potent NK cell activation in an ex vivo analysis, compared to Fc-enhanced IgG1 antibodies. Further, AFM28 was well tolerated and showed pharmacodynamic activity in cynomolgus monkeys. Preliminary Cash Balance and Cash Runway Guidance As of December 31, 2021, Affimed’s preliminary unaudited cash and cash equivalents were approximately €197 million. The cash balance includes €7.4 million of net proceeds received from the second tranche of Affimed’s loan agreement with Silicon Valley Bank, which was drawn in December 2021. Based on its current operating plan and assumptions, Affimed anticipates that its cash and cash equivalents will support operations into the second half of 2023.
Per 31 dec 197 miljoen in kas, waaronder 7,4 uit inkomsten. Per 31 sep was er 198,7 miljoen in kas. Uitgaven kwamen toen op ruim 25 miljoen per kwartaal. Dan lijkt het er toch op dat er een kleine heimelijke emissie heeft plaatsgevonden de voorbije weken, waar o.a. Tom al van uitging. Anders zou de kas nu dichter bij de 150 miljoen moeten zitten...
All three patients treated at the RP2D with at least 6 months of follow-up remained in complete response as of the cutoff date. Dit lijkt me ook goed nieuws. Ook de emissie in de nadagen van 2021 is goed nieuws gezien de barre omstandigheden nu.
De emissieactiviteiten in Q4 besloegen nog niet de helft van wat er mogelijk was ($100 miljoen) :www.davispolk.com/experience/affimed-...
Tom3 schreef op 6 januari 2022 12:54 :
All three patients treated at the RP2D with at least 6 months of follow-up remained in complete response as of the cutoff date.
Dit lijkt me ook goed nieuws.
Dat lijkt me een verwijzing naar wat ze in dec naar buiten brachten. Geen nieuwe update mbt de cr's, volgens mij.
Tom3 schreef op 6 januari 2022 13:14 :
De emissieactiviteiten in Q4 besloegen nog niet de helft van wat er mogelijk was ($100 miljoen) :
www.davispolk.com/experience/affimed-... Dichter bij een kwart zelfs... 198 + 7 - 25 = 180. 197 - 180 = 17. Ervan uitgaande dat de q4 uitgaven wederom 25 miljoen betroffen.
Hulskof schreef op 6 januari 2022 13:36 :
[...]
Dichter bij een kwart zelfs...
198 + 7 - 25 = 180.
197 - 180 = 17.
Ervan uitgaande dat de q4 uitgaven wederom 25 miljoen betroffen.
Bovenstaande bedragen zijn weliswaar in euro's. €17 miljoen euro is ongeveer $19 miljoen.
Hulskof schreef op 6 januari 2022 13:29 :
[...]
Dat lijkt me een verwijzing naar wat ze in dec naar buiten brachten.
Geen nieuwe update mbt de cr's, volgens mij.
In november was de peildatum 31 oktober.
Wat is er bij CRIS aan de hand? De biotech doet het vandaag weer bere-slecht maar CRIS spant de kroon. Ik zie geen nieuws.... Je vraagt je af wat de waarde is van het persbericht van AFMD vandaag. Beleggers zijn manisch depressief geworden.
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Nieuwsberichten
Artikelen
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antares
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Belreca
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
EMD Music
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genk Logistics Cert.
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
Kortrijk Shop. Cert.
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Lux-Airport Cert
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
MediVision
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
Neufcour (Compagnie Financière de)
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Option Trading Company
Orange Belgium
Oranjewoud
Orcobsaar1219
Ordina Beheer
Oud ForFarmers
Outotec
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
PCB
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
RealDolmen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Rosier
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Sabca
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shanks Group
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sint Gudule Plaats Cert.
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Systeem Trading
Team Kalorik
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Ter Beke
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
THEMIS BIOSCIENCE
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Unitronics
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
Wolters Kluwer
Woluwe Uitbreiding
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Zetes Industries
Ziggo
Zilver - Silver World Spot (USD)
Affimed NV
Meer »
Koers
0,880
Verschil
+0,02
(+2,65% )
Laag
0,825
Volume
530.811
Hoog
0,899
Gem. Volume
758.667
31 mei 2023 22:00
Premium
Neem nu een abonnement op IEX en krijg toegang tot onze koop-en verkooptips!
Word abonnee